Skip to content
value.today

TearScience, Inc.

Total raised
$59 M
2 rounds on record
Latest round
$19 M
Mar 2016
First round on record
May 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of TearScience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2016$19 MNo. 2$10 to $50 million

TearScience, Inc.: Raise no. 2, Mar 2016

Investors in this round

14 investors had bought by the notice of Apr 14, 2016: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $29 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joe Boorady · Executive Officer, Director
  • Manoj George · Executive Officer
  • Abhijeet Lele · Director
  • Immanuel Thangaraj · Director
  • Joe Mandato · Director
  • Joel Cutler · Director
  • Todd Davis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joe Boorady, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 14, 2016. Read the notice at the SEC.

equity, optionsSEC
May 2010$40 MNo. 1$10 to $50 million

TearScience, Inc.: Raise no. 1, May 2010

Investors in this round

12 investors had bought by the notice of May 17, 2010: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $45 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Nicole R. Wicker · Executive Officer
  • Timothy R. Willis · Executive Officer, Director
  • Donald R. Korb · Director
  • Geoff R. Pardo · Director
  • Jim R. Largent · Director
  • Joe R. Mandato · Director
  • Matthew R. Rieke · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy R. Willis, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 17, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • TearScience, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2016).

    SEC Form D · Apr 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2016

That is all the official record says: TearScience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of TearScience, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TearScience, Inc.
NameRoleNamed in
Joe BooradyExecutive officerApr 2016
Manoj GeorgeExecutive officerApr 2016
Nicole R. WickerExecutive officerMay 2010
Timothy R. WillisExecutive officerMay 2010
Abhijeet LeleDirectorApr 2016
Immanuel ThangarajDirectorApr 2016
Joe BooradyDirectorApr 2016
Joe MandatoDirectorApr 2016
Joel CutlerDirectorApr 2016
Todd DavisDirectorApr 2016
Donald R. KorbDirectorMay 2010
Geoff R. PardoDirectorMay 2010
Jim R. LargentDirectorMay 2010
Joe R. MandatoDirectorMay 2010
Matthew R. RiekeDirectorMay 2010
Timothy R. WillisDirectorMay 2010